Compare SW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SW | INSM |
|---|---|---|
| Founded | 1934 | 1988 |
| Country | Ireland | United States |
| Employees | 97000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6B | 23.0B |
| IPO Year | N/A | 2000 |
| Metric | SW | INSM |
|---|---|---|
| Price | $43.32 | $97.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $53.58 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 4.5M | 3.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.43 | $182.31 |
| Revenue Next Year | $3.13 | $65.19 |
| P/E Ratio | $38.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.73 | $90.39 |
| 52 Week High | $52.65 | $212.75 |
| Indicator | SW | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 38.93 |
| Support Level | $40.38 | N/A |
| Resistance Level | $44.61 | $166.81 |
| Average True Range (ATR) | 1.74 | 4.96 |
| MACD | 0.27 | 0.39 |
| Stochastic Oscillator | 95.60 | 40.70 |
Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.